EUVIMEDEUVIMED entdecken
Crossref

Cost‐Utility Analysis of Biomarker‐Based vs. USG + AFP Strategies for HCC Surveillance in Chronic Hepatitis B

Tanat Saeoui iD, Chayanis Kositamongkol iD, Ratthanan Chantrakul iD, Pimsiri Sripongpun iD, Naichaya Chamroonkul iD, Chanon Kongkamol iD, Pochamana Phisalprapa iD, Apichat Kaewdech iD

Alimentary Pharmacology & Therapeutics · 2026

DOI: 10.1111/apt.70386 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Tanat Saeoui und 7 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Hepatology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Hepatitis B, Chronic, alpha-Fetoproteins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Faculty of Medicine, Prince of Songkla University, The Gastroenterological Association of Thailand (GAT), Guardian Angel Thrift.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The standard surveillance for hepatocellular carcinoma (HCC) involves ultrasound (USG) with alpha‐fetoprotein (AFP) every 6 months. However, limitations, such as restricted access, radiologist shortages, and uncertain cost‐effectiveness, persist.

Aims

We assessed the cost‐effectiveness of traditional and biomarker‐based HCC surveillance strategies in patients with chronic hepatitis B (CHB).

Methods

A Markov model simulated a cohort of patients with CHB to evaluate the cost‐effectiveness of various surveillance strategies: USG + AFP, GAAD, GALAD, ASAP, and no surveillance. Input parameters were sourced from literature and Thai healthcare data. The analysis adopted a societal perspective and lifetime horizon, calculating incremental cost‐effectiveness ratios (ICERs) in Thai Baht (THB) per quality‐adjusted life year (QALY) gained. Sensitivity analyses assessed robustness.

Results

ASAP every 6 months was the most cost‐effective strategy, with ICERs of 102,443 THB (~2957 USD) per QALY versus ASAP every 12 months and 76,447 THB (~2207 USD) per QALY versus no surveillance. Although GAAD and GALAD every 6 months achieved similar QALYs, they were dominated due to higher costs. Annual surveillance improved cost‐effectiveness but remained inferior to ASAP every 6 months. USG + AFP every 6 months incurred the highest lifetime cost (166,253 THB, ~4800 USD). Sensitivity analyses confirmed the robustness of ASAP every 6 months, with key drivers including biomarker costs, HCC stage utilities, and incidence rates.

Conclusions

ASAP every 6 months is the most cost‐effective HCC surveillance strategy for patients with CHB and may be particularly suitable for resource‐limited settings. Biomarker‐based surveillance should be prioritised to improve outcomes and optimise resource use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHepatitis B, Chronicalpha-FetoproteinsBiomarkers, TumorHumansCost-Benefit AnalysisBiomarkersMarkov ChainsUltrasonographyQuality-Adjusted Life YearsMaleFemaleMiddle AgedThailand

Stichwörter der Autor:innen

biomarkerscirrhosiscost‐utility analysishepatitis Bsurveillanceultrasonography

Substanzen

alpha-FetoproteinsBiomarkersBiomarkers, Tumor

Autor:innen und Institutionen

  • Gastroenterology and Hepatology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
  • Division of Ambulatory Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Division of Family and Preventive Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
  • Division of Digital Innovation and Data Analytics, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.

ORCID-Profile: Tanat Saeoui, Chayanis Kositamongkol, Ratthanan Chantrakul, Pimsiri Sripongpun, Naichaya Chamroonkul, Chanon Kongkamol, Pochamana Phisalprapa, Apichat Kaewdech

Förderung

  • Faculty of Medicine, Prince of Songkla University
  • The Gastroenterological Association of Thailand (GAT)
  • Guardian Angel Thrift

Zitieren

APA

Saeoui, T., Kositamongkol, C., Chantrakul, R., Sripongpun, P., Chamroonkul, N., Kongkamol, C., Phisalprapa, P., & Kaewdech, A. (2026). Cost‐Utility Analysis of Biomarker‐Based vs. USG + AFP Strategies for HCC Surveillance in Chronic Hepatitis B. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70386

Vancouver

Saeoui T, Kositamongkol C, Chantrakul R, Sripongpun P, Chamroonkul N, Kongkamol C, et al. Cost‐Utility Analysis of Biomarker‐Based vs. USG + AFP Strategies for HCC Surveillance in Chronic Hepatitis B. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70386

BibTeX
@article{Saeoui2026,
  author = {Saeoui, Tanat and Kositamongkol, Chayanis and Chantrakul, Ratthanan and Sripongpun, Pimsiri and Chamroonkul, Naichaya and Kongkamol, Chanon and Phisalprapa, Pochamana and Kaewdech, Apichat},
  title = {Cost‐Utility Analysis of Biomarker‐Based vs. USG + AFP Strategies for HCC Surveillance in Chronic Hepatitis B},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1111/apt.70386}
}
Kostenlos starten →